NGS-Guided Precision Oncology in Breast Cancer and Gynecological Tumors : A Retrospective Molecular Tumor Board Analysis
Loading...
Date
Publisher
Philipps-Universität Marburg
Abstract
Identifying the mutational landscape of tumors using next-generation sequencing
(NGS) has become substantially more common over the past decade, especially in patients with
advanced tumors. However, there is still limited real-world evidence for the clinical benefits of
NGS-guided precision oncology. This retrospective analysis of breast and gynecological cancer
patients referred to our center’s multidisciplinary Molecular Tumor Board revealed that treatment
recommendations were provided to 63.3% of patients, of whom 29.1% received molecular-matched
treatment resulting in significantly prolonged progression-free survival. Commonly altered genes
included TP53, PIK3CA, BRCA1/2, and ARID1A. Overall, NGS-guided precision oncology using
panel diagnostics demonstrated improved clinical outcomes in a subset of patients with breast and
gynecological cancers in a real-world setting.